Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J K Joseph

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|June 15, 2011
Programmatic management of multidrug-resistant tuberculosis: models from three countriesJ Furin, J Bayona, M Becerra, et al.
Molecular Imaging and Biology|April 29, 2016
Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus MonkeysDean O Campbell, Akihiro Noda, Alla Verlinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft modelsDebra Ferguson, Luis E Rodriguez, Joann P Palma, et al.
Mabs|June 24, 2011
Development of an Fn14 agonistic antibody as an anti-tumor agentJennifer S Michaelson, Aldo Amatucci, Rebecca Kelly, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 23, 2003
Clinical and programmatic considerations in the treatment of MDR-TB in children: a series of 16 patients from Lima, PeruJ S Mukherjee, J K Joseph, M L Rich, et al.
Journal of Medicinal Chemistry|March 19, 2004
Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse modelTricia J Vos, Andrei Caracoti, Jennifer L Che, et al.
Mabs|March 12, 2011
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activityJianying Dong, Arlene Sereno, Dikran Aivazian, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|June 15, 2011
Programmatic management of multidrug-resistant tuberculosis: models from three countriesJ Furin, J Bayona, M Becerra, et al.
Molecular Imaging and Biology|April 29, 2016
Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus MonkeysDean O Campbell, Akihiro Noda, Alla Verlinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft modelsDebra Ferguson, Luis E Rodriguez, Joann P Palma, et al.
Mabs|June 24, 2011
Development of an Fn14 agonistic antibody as an anti-tumor agentJennifer S Michaelson, Aldo Amatucci, Rebecca Kelly, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 23, 2003
Clinical and programmatic considerations in the treatment of MDR-TB in children: a series of 16 patients from Lima, PeruJ S Mukherjee, J K Joseph, M L Rich, et al.
Journal of Medicinal Chemistry|March 19, 2004
Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse modelTricia J Vos, Andrei Caracoti, Jennifer L Che, et al.
Mabs|March 12, 2011
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activityJianying Dong, Arlene Sereno, Dikran Aivazian, et al.
Pageof 2